RXi Pharmaceuticals Corporation Warrants expiring 12/16/2021
RXIIW
RXIIW was delisted on the 16th of November, 2018.
0 hedge funds and large institutions have $0 invested in RXi Pharmaceuticals Corporation Warrants expiring 12/16/2021 in 2018 Q4 according to their latest regulatory filings, with funds opening new positions, increasing their positions, 0 reducing their positions, and 4 closing their positions.
100% less funds holding
Funds holding: 4 → 0 (-4)
100% less capital invested
Capital invested by funds: $401K → $0 (-$401K)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 4
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AFM
Anson Funds Management
Dallas,
Texas
|
-$255K |
| 2 |
CH
CVI Holdings
Wilmington,
Delaware
|
-$77K |
| 3 |
SM
Sabby Management
Miami Beach,
Florida
|
-$68K |
| 4 |
LTFS
Ladenburg Thalmann Financial Services
Miami,
Florida
|
-$1K |
RXIIW Hedge Fund Activity: Q4 2018 in Review
0 of the 4,489 institutional investors tracked by Wall St. Rank reported a position in RXi Pharmaceuticals Corporation Warrants expiring 12/16/2021 (RXIIW) for Q4 2018, worth a combined $0 — down 100% from $401K a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of RXIIW and 0 opened new positions — a net loss of 4 holders — while 0 trimmed existing stakes and 0 added.
The largest seller was Anson Funds Management, exiting entirely with an estimated $255K sold.
- 0 institutional investors held RXi Pharmaceuticals Corporation Warrants expiring 12/16/2021 (RXIIW) as of Q4 2018, down from 4 in Q3 2018.
- Funds reported $0 of RXi Pharmaceuticals Corporation Warrants expiring 12/16/2021 stock for Q4 2018, down 100% quarter-over-quarter.
- 0 funds opened new RXi Pharmaceuticals Corporation Warrants expiring 12/16/2021 positions in Q4 2018 and 4 closed out, a net change of -4 holders.
- The largest RXi Pharmaceuticals Corporation Warrants expiring 12/16/2021 seller in Q4 2018 was Anson Funds Management, an estimated $255K sold.
Based on aggregated 13F filings for Q4 2018.